Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is xeroderma pigmentosum a contraindication for adjuvant radiation therapy to the breast in the breast conservation setting?
Answer from: Radiation Oncologist at Community Practice
It’s not a contraindication to RT as DSB caused by ionizing RT is not the same as damage caused by exposure to UV rays.
Sign In
or
Register
to read more
8736
Related Questions
Do you omit PMRT for patients who would have been eligible for NSABP B-51, but are found to have significant pure LVSI only, without stromal carcinoma, after neoadjuvant chemotherapy?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
What volumes and dose would you use for a chest wall recurrence in a patient who had previous mastectomy and completed only a partial prior course of PMRT?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
How do you manage symptomatic fat necrosis following adjuvant breast radiotherapy?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
How will the LORETTA and COMET trials influence your treatment of low-risk DCIS?
What are your top takeaways in Radiation Oncology from SABCS 2025?
For a patient who previously underwent PBI and then developed a second ipsilateral primary, would you offer repeat PBI?